[HTML][HTML] Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish …

MA Gram, HD Emborg, AB Schelde, NU Friis… - PLoS …, 2022 - journals.plos.org
Background The continued occurrence of more contagious Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) variants and waning immunity over time require ongoing …

Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series …

CH Hansen, AB Schelde, IR Moustsen-Helm… - MedRxiv, 2021 - medrxiv.org
In this brief communication we are showing original research results with early estimates
from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-…

[HTML][HTML] Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study

KF Nielsen, IR Moustsen-Helms, AB Schelde… - PLoS …, 2022 - journals.plos.org
Background Individuals with a prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
infection have a moderate to high degree of protection against reinfection, …

Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk …

HD Emborg, P Valentiner-Branth, AB Schelde… - MedRxiv, 2021 - medrxiv.org
Objective To estimate in a real life setting, the vaccine effectiveness of the BNT162b2 mRNA
vaccine against confirmed SARS-CoV-2 infection, hospital admission, and death among …

[HTML][HTML] Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA …

MA Gram, J Nielsen, AB Schelde, KF Nielsen… - PLoS …, 2021 - journals.plos.org
Background The recommendations in several countries to stop using the ChAdOx1 vaccine
has led to vaccine programs combining different Coronavirus Disease 2019 (COVID-19) …

Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide …

MA Gram, HD Emborg, AB Schelde, NU Friis… - medRxiv, 2022 - medrxiv.org
Background The continued occurrence of more contagious SARS-CoV-2 variants and waning
immunity over time require ongoing re-evaluation of the vaccine effectiveness (VE). This …

[HTML][HTML] GLP-1 based therapies and disease course of inflammatory bowel disease

M Villumsen, AB Schelde, E Jimenez-Solem… - …, 2021 - thelancet.com
Background The disease course of inflammatory bowel disease (IBD) following treatment
with glucagon-like peptide (GLP)-1 based therapies is unclear. The aim of this study was to …

Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose

MA Gram, J Nielsen, AB Schelde, KF Nielsen… - MedRxiv, 2021 - medrxiv.org
Background The recommendations in several countries to stop using the ChAdOx1 vaccine
has led to vaccine programs combining different vaccine types, which necessitates new …

Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis

…, K Schmiegelow, C Rechnitzer, AB Schelde… - Critical Reviews in …, 2020 - Elsevier
A substantial proportion of cancer patients experience chemotherapy-induced nausea and
vomiting (CINV) despite the use of antiemetic drugs. Prevalent genetic polymorphisms …

[HTML][HTML] Validation studies in epidemiologic research: estimation of the positive predictive value

AB Schelde, J Kornholt - Journal of Clinical Epidemiology, 2021 - Elsevier
Astrid Blicher Schelde was supported by a grant from Danish Regions [grant number:
EMN-2017-00901]. Jonatan Kornholt was supported by a grant from Velux Foundation [grant …